Slide 1: Glenmark Life Sciences exchange filing: Investor Presentation
6 qtenmaRk LIFE SCIENCES Partnership, Innovation. Passion. April 20, 2022 To, To, Dy. General Manager The Manager - Listing, Department of Corporate Services, National Stock Exchange of India Ltd., BSE Ltd., Plot No. C/1, G Block, P. J. Towers, Dalal Street, Bandra Kurla Complex, Fort, Mumbai - 400
Slide 2: Q4 FY22 Investor Presentation
Q4 FY22 Investor Presentation Glenmark Life Sciences Ltd
Slide 3: Financial Performance Review
01 Financial Performance Review
Slide 4: Q4 FY22 – Highlights
Q4 FY22 – Highlights Dr. Yasir Rawjee Revenue Managing Director • YoY Revenue grew at 10.0% in Q4 and INR 5,141 mn & 12.6% in FY 22 Chief Executive Officer • The year witnessed strong growth momentum across key regulated markets “Our sustained growth in FY22 YoY, 10.0% QoQ, -1.6% with solid profitab
Slide 5: P&L Highlights – Q4 & FY22
P&L Highlights – Q4 & FY22 Amounts in INR Millions Q4 FY22 Q3 FY22 QoQ Q4 FY21 YoY FY22 FY21 YoY Revenue from Operations 5,140.6 5,225.0 -1.6% 4,671.6 10.0% 21,232.1 18,851.7 12.6% Gross Profit 2,589.3 2,653.3 -2.4% 2,746.9 -5.7% 10,803.3 9,796.7 10.3% Gross Profit (%) 50.4% 50.8% 58.8% 50.9% 52.0%
Slide 6: Key Balance Sheet Items and Cash flow
Key Balance Sheet Items and Cash flow Key Balance Sheet Items Free Cash Flow As at 31st As at 31st Amounts in INR Millions FY22 FY21 Amounts in INR Millions Mar'22 Mar'21 Equity 20,543.1 7,527.5 Profit Before Tax 5,649.3 4,709.4 Total Debt - 9,328.7 Adjustment for Non Operating Items* 709.9 1,333.1
Slide 7: Quarter on Quarter Performance
Quarter on Quarter Performance Sustaining a profitable growth trajectory despite cost headwinds 36.4% 5,618 3 7 . 0 % 31.3% 28.7% 5,249 5,225 5,141 30.2% 28.6% 3 2 . 0 % 1 ,5 0 0 4,672 2 7 . 0 % 2 2 . 0 % 1,702 1,694 1 7 . 0 % 1,644 1 ,0 0 0 1,496 1,473 1 2 . 0 % 7 .0 % 2 .0 % Revenue 5 0 0 -3 . 0 %
Slide 8: Financial Performance Track Record
Financial Performance Track Record Robust growth and profitability indicators over the years 3 5 . 0 % CAGR 15.3% 31.5% 31.4% 21,232 6 ,0 0 0 30.6% 29.7% 18,852 27.6% 3 0 . 0 % 5 ,0 0 0 15,373 14,050 2 5 . 0 % 12,017 4 ,0 0 0 6,308 5,919 2 0 . 0 % 4,840 3 ,0 0 0 4,298 2 ,0 0 0 3,317 1 5 . 0 % Revenu
Slide 9: Strong Returns Indicators
Strong Returns Indicators ROCE Fixed Assets Turnover Working Capital Days 33% FY19 FY20 FY21 FY22 33% 3.3 3.4 32% 3 5 0 2 5 0 202 2.9 176 3 0 0 173 2 0 0 31% 2.7 152 2.5 2 5 0 98 1 5 0 2 0 0 1 5 0 104 99 89 1 0 0 29% 1 0 0 152 5 0 5 0 116 120 116 - - - 5 0 -47 -48 -43 -53 - 5 0 AR Days AP Days FY18
Slide 10: Business Performance Review
02 Business Performance Review
Slide 11: Segment Performance
Segment Performance 19,154 17,084 2,005 Revenue (₹ Mn) Revenue (₹ Mn) 12,627 12,939 1,720 1,530 11,180 981 487 Generic API CDMO FY 18 FY 19 FY 20 FY 21 FY 22 FY 18 FY 19 FY 20 FY 21 FY 22 • Generic API revenues in Q4FY22 increased • CDMO revenues registered growth of 12.5% in 89% 12.5% YoY 8% FY22 •
Slide 12: Market and Therapeutic Area Mix
Market and Therapeutic Area Mix 28% 29% 27% 28% 34% 37% 32% 36% 37% 39% 5% 6% 4% 4% 5% 10% 8% 7% 9% 7% 9% 9% 8% 9% 14% 72% 71% 73% 72% 66% 40% 40% 45% 42% 38% Therapeutic Market Mix FY 18 FY 19 FY 20 FY 21 FY 22 FY 18 FY 19 FY 20 FY 21 FY 22 Regulated Markets Emerging Markets Area Mix CVS CNS Diabet
Slide 13: Company Overview
03 Company Overview G Glenmark LIFE SCIENCES
Slide 14: Global Footprint
Global Footprint Filed 433 DMFs and CEPs across major markets; United States, Europe, Japan, Russia, Brazil, South Korea, Taiwan, Canada, China and Australia ROW 60+ 350+ 30+ 88 116 150 10+ 17 120+ 50+ 62 (Brazil) India – Mix of Regulated Number of Number of customers Regulated Markets Emerging Mark
Slide 15: Quality-focused, compliant manufacturing & R&D infrastructure
Quality-focused, compliant manufacturing & R&D infrastructure Manufacturing Infrastructure R&D Infrastructure Annual Installed Capacity (Mar-22) Last USFDA Inspection Date Approvals Mahape, Navi Mumbai USFDA, MHRA (UK), FIMEA R&D for new product development (Finland), Romania (Europe) and complex
Slide 16: R&D Capabilities
R&D Capabilities 6 5 0 5 .0 % 572 4 .5 % Cumulative Filing Status 5 5 0 4 .0 % 400 405 North 4 5 0 376 3 .5 % Therapy Europe Japan Brazil ROW Total 3 5 0 2.7% 2.6% 2.7% 3 .0 % America 2.1% 2 .5 % CVS 36 30 4 16 35 121 2 5 0 2 .0 % CNS 35 19 7 12 12 85 Diabetes 9 3 - 7 10 29 1 5 0 1 .5 % 5 0 1 .0 % P
Slide 17: Strategy Going Forward
04 Strategy Going Forward G Glenmark LIFE SCIENCES
Slide 18: Strategic Growth Levers
Strategic Growth Levers •New product launches •Ramp up CDMO portfolio •Geographical expansion •Expand into complex API platforms •Focus on new markets becoming •Iron compounds more regulated •Oncology •Pursue 2nd source opportunities with top generic players New Gx API Growth Business levers Operati
Slide 19: Future Capacity Expansion Plan
Future Capacity Expansion Plan Expansion Type Division Location Current Capacity Status & Planned Capacity Operational Timelines Under Construction Phase I – Q4FY22 Brownfield API Dahej 141.9 KL 4 Modules -240 KL Phase II – Q2 FY23 New plant Brownfield Intermediate Ankleshwar 550.2 KL Q2 FY23 400 KL
Slide 20: Thank You
Thank You Glenmark Life Sciences Limited Corporate Office: 4th Floor, OIA House, 470, Cardinal Gracious Road, Andheri (E), Mumbai, 400 099, India. Registered Office: Plot No. 170-172, Chandramouli Industrial Estate, Mohol Bazarpeth, Solapur - 413 213, India. T: 91 22 68297979 CIN: U74900PN2011PLC13996